Trump et al. focus on NIH, cancer—and how peer review is done

HHS halts nearly $500M in mRNA-related vaccine contracts

The Department of Health and Human Services has announced the start of a reduction in its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority.

August 08, 2025

Vol.51 No.31

By Claire Marie Porter

Podcast

In The Headlines: A good week for NIH, a bad week for Vinay Prasad

While doing somewhat-routine reporting on this year’s Senate Appropriations Committee bills, Paul Goldberg, editor and publisher of The Cancer Letter, quickly realized that he was seeing a full bipartisan rejection of President Donald J. Trump’s plan to defund and therefore dismantle biomedical research in the United States.

August 06, 2025

Vol.51 No.30

Capitol Hill

GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise

Bits of good news for NIH flickered consistently over the past week.

August 01, 2025

Vol.51 No.30

By Paul Goldberg

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya

In a move that will have direct impact on approval of cancer drugs, George Francis Tidmarsh, an oncologist and a longtime pharmaceutical executive, was named director of the FDA Center for Drug Evaluation and Research.

July 25, 2025

Vol.51 No.29

By Claire Marie Porter

Cancer Policy

The effects of NIH, FDA cuts will be felt for decades, CBO report estimates

A report from the nonpartisan Congressional Budget Office said that proposed cuts at NIH could lead to a decrease in the number of new drugs that come to market in the next three decades.

NIH says it’s moving away from animal-based models

NIH has announced that it will no longer be issuing Notices of Funding Opportunities exclusively supporting animal models.

July 18, 2025

Vol.51 No.28

By Claire Marie Porter

Trump et al. focus on NIH, cancer—and how peer review is done

YOU MAY BE INTERESTED IN

HHS halts nearly $500M in mRNA-related vaccine contracts

In The Headlines: A good week for NIH, a bad week for Vinay Prasad

GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya

The effects of NIH, FDA cuts will be felt for decades, CBO report estimates

NIH says it’s moving away from animal-based models

Renew today!

Subscriber content

Never miss an issue!

Login

Trump et al. focus on NIH, cancer—and how peer review is done

YOU MAY BE INTERESTED IN

HHS halts nearly $500M in mRNA-related vaccine contracts

In The Headlines: A good week for NIH, a bad week for Vinay Prasad

GOP-led Congress rejects Trump’s plans to gut medical researchSenate bill gives NIH a $400 million raise

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER directorHis appointment came out of “proximity” to Makary and Bhattacharya

The effects of NIH, FDA cuts will be felt for decades, CBO report estimates

NIH says it’s moving away from animal-based models

Never miss an issue!

Login

GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya